Clinical laboratory · 2026
Interference of Daratumumab Treatment in the Biological Monitoring of Multiple Myeloma.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Skalante O, Eddair Y, Elidrissi Z, Echiguer C, Bella-Tedga R, Biaz A, Bouhsain S, Elmaaroufi H, Dami A, El-Machtani-Idrissi S
Аннотация
BACKGROUND: Multiple myeloma is a plasma cell malignancy characterized by monoclonal immunoglobulin production. Daratumumab has improved therapeutic outcomes but can interfere with laboratory assessments.
METHODS: A 73-year-old woman with IgG kappa multiple myeloma achieved remission after initial treatment, then relapsed and received DRD. A monoclonal IgG kappa spike was observed on follow-up SPEP and IFE.
RESULTS: Daratumumab, due to its IgG1 kappa structure, may mimic disease-related monoclonal proteins, potentially leading to false detection of residual disease and misclassification of complete response as very good partial response.
CONCLUSIONS: Recognizing such interference and ensuring strong clinician-biologist collaboration is essential for accurate response interpretation.
METHODS: A 73-year-old woman with IgG kappa multiple myeloma achieved remission after initial treatment, then relapsed and received DRD. A monoclonal IgG kappa spike was observed on follow-up SPEP and IFE.
RESULTS: Daratumumab, due to its IgG1 kappa structure, may mimic disease-related monoclonal proteins, potentially leading to false detection of residual disease and misclassification of complete response as very good partial response.
CONCLUSIONS: Recognizing such interference and ensuring strong clinician-biologist collaboration is essential for accurate response interpretation.